Analysts expect BioCorRx Inc. to report revenue of 223,285.20 for Q2 26, against a range of 214,401.58 to 232,168.82. The most recent reported quarter, Q1 26, came in at 214,539.00, a 2.8% beat against the 208,756.90 consensus.
| Metric | Q3 22 | Q1 23 | Q2 23 | Q3 23 | Q1 25 | Q2 25 | Q3 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 94,440.00 | 40,440.00 | 19,640.00 | 10,140.00 | 130,000.00 | 180,000.00 | 635,224.00 | 214,539.00 | - | - | - | - | - | - | - | - | |||
| High Estimate | - | - | - | - | - | - | 208,992.21 | 227,960.86 | 232,168.82 | 257,178.80 | 284,890.05 | 366,591.78 | 335,541.72 | 307,412.79 | 339,388.46 | 632,162.79 | |||
| Low Estimate | - | - | - | - | - | - | 190,532.19 | 189,552.94 | 214,401.58 | 223,778.70 | 257,870.35 | 314,050.30 | 298,610.00 | 274,246.57 | 302,389.94 | 549,011.65 | |||
| Consensus Estimate | - | - | - | - | - | - | 199,762.20 | 208,756.90 | 223,285.20 | 240,478.75 | 271,380.20 | 340,321.04 | 317,075.86 | 290,829.68 | 320,889.20 | 590,587.22 |
Analysts expect BioCorRx Inc. to report earnings per share of -0.06 for Q3 25, against a range of -0.06 to -0.06. The most recent reported quarter, Q1 26, came in at -0.13, a 113.9% miss against the -0.06 consensus.
| Metric | Q3 22 | Q1 23 | Q2 23 | Q3 23 | Q1 25 | Q2 25 | Q3 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.13 | -0.13 | -0.11 | -0.10 | -0.06 | -0.07 | - | -0.13 | - | - | - | - | - | - | - |
| High Estimate | - | - | - | - | - | - | -0.06 | -0.06 | -0.05 | -0.05 | -0.05 | -0.06 | -0.04 | -0.03 | -0.03 |
| Low Estimate | - | - | - | - | - | - | -0.06 | -0.06 | -0.05 | -0.05 | -0.05 | -0.06 | -0.04 | -0.03 | -0.03 |
| Consensus Estimate | - | - | - | - | - | - | -0.06 | -0.06 | -0.05 | -0.05 | -0.05 | -0.06 | -0.04 | -0.03 | -0.03 |